Ani Pharmaceuticals (ANIP) Cash from Financing Activities (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Cash from Financing Activities data on file, last reported at -$21.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 118.21% year-over-year to -$21.6 million; the trailing twelve-month figure through Mar 2026 stood at -$21.7 million (down 107.88% YoY), and the FY2025 full-year result was -$9.9 million, down 103.75% from the prior year.
• Cash from Financing Activities eased to -$21.6 million in Q1 2026, from -$4.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $291.0 million in Q3 2024 to a low of -$21.6 million in Q1 2026.
• A 5-year average of $17.4 million and a median of -$1.7 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 2246.06% in 2023 and jumped 7650.47% in 2024, its largest moves.
• Tracing ANIP's Cash from Financing Activities over 5 years: stood at -$508000.0 in 2022, then plunged by 2246.06% to -$11.9 million in 2023, then surged by 58.83% to -$4.9 million in 2024, then increased by 5.52% to -$4.6 million in 2025, then sank by 366.26% to -$21.6 million in 2026.
• Business Quant data shows ANIP's Cash from Financing Activities at -$21.6 million in Q1 2026, -$4.6 million in Q4 2025, and $6.3 million in Q3 2025.